When I was on an active hormone blockade (ADT2) I suffered extensively from many of the usually reported morbidity issues (negative side effects). One of the side effects I dealt with was significant cognitive impairment. I live in New York City, was born in the city and have spent most of my life in the [...]
I have returned from Michigan and again have the computer access and the time to continue sharing items relevant to our struggle. Investigators at the Duke University Prostate Center have indicated that cholesterol-lowering drugs, statins, may reduce inflammation in prostate tumors, which might hinder prostate cancer growth. "Previous studies have shown that men taking statins [...]
Not a very big surprise but androgen-deprivation therapy (ADT) substantially increases the risk for cardiovascular and bone-related problems, as well as for diabetes, according to a review of the medical literature published online April 27 in the journal Cancer. At the University of Texas Health Science Center in Houston, Lockwood G. Taylor wrote a review [...]
Prior to the AUA meeting Dendreon released the following to its investors. We will now wait to see what transpires at the AUA meeting which is scheduled to be held in one and a half hours from my posting this. Joel T Nowak MA, MSW – Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival [...]
I don't know about you, but I am waiting very anxiously for today's presentation at the AUA conference from Dendreon about Provenge. It is an absolute shame that we have been put into the position that we needed to wait for more men to die before moving ahead. I am concerned that all of the [...]
Press Release: Dendreon Corporation (Nasdaq: DNDN) announced the following data presentations taking place at the American Urological Association's (AUA) Annual Meeting in Chicago, as well as a Dendreon-sponsored IMPACT data webcast conference call: (for those of us who will be unable to attend the session at AUA in Chicago) April 28, 2009, 2:20 p.m. CDT-"A [...]
A phase II trial was just completed at the University of Western Australia to investigate changes in bone mineral density (BMD) and osteoporosis in men on intermittent androgen-suppression therapy (IAST) over a period of three years. This trial, conducted at the Faculty of Medicine, University of Western Australia, Crawley, Department of Radiation Oncology, Sir Charles [...]
As a follow up to yesterday's news about the positive results announced about Provenge, I have received a number of private emails asking questions about the treatment. I hope that the following will answer many of the questions people might still have about Provenge. • The other name for Provenge is sipuleucel-T. • Provenge is [...]
The doctor has just scribbled a new prescription and now the pharmacist must translate it when they fill the order. What does all those chicken scrawls mean? Here is an example of what a prescription could look like- “drug name 250 mg Ac bid x 10 days?” To start, the first part of a prescription [...]
A recent report from England, about the first-generation oral bisphosphonate sodium clodronate, claims to improve overall survival in men with metastatic but not localized prostate cancer, according to long-term data from two randomized controlled trials. Among the sample of 278 men all who had metastatic disease starting and who were responding to long-term hormone therapy, [...]
